Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma

Activating BRAF or NRAS mutations have been found in 80% of human sporadic melanomas, but only one of these genetic alterations could be detected in each tumour. This suggests that BRAF and NRAS ‘double mutants’ may not provide advantage for tumour growth, or may even be selected against during tumorigenesis. However, by applying mutant-allele-specific-amplification-PCR method to short-term melanoma lines, one out of 14 tumours was found to harbour both BRAFV600E and the activating NRASQ61R mutations. On the other hand, analysis of 21 melanoma clones isolated by growth in soft agar from this tumour indicated that 16/21 clones harboured a BRAFV600E, but were wild-type for NRAS, whereas the remaining had the opposite genotype (NRASQ61R/wild-type BRAF). When compared to BRAFV600E clones, NRASQ61R clones displayed reduced growth in soft agar, but higher proliferative ability in vitro in liquid medium and even in vivo after grafting into SCID/SCID mice. These data suggest that NRAS and BRAF activating mutations can coexist in the same melanoma, but are mutually exclusive at the single-cell level. Moreover, the presence of NRASQ61R or BRAFV600E is associated with distinct in vitro and in vivo growth properties of neoplastic cells.

[1]  A. Anichini,et al.  N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma , 1994, Melanoma research.

[2]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[3]  J. Downward.  Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells , 2004, Oncogene.

[4]  J. Rak,et al.  Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand". , 2004, Seminars in cancer biology.

[5]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[6]  Channing J Der,et al.  Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? , 2004, Trends in cell biology.

[7]  C. Pritchard,et al.  Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.

[8]  J. Joyce,et al.  Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.

[9]  M. Hendrix,et al.  Remodeling of the Microenvironment by Aggressive Melanoma Tumor Cells , 2003, Annals of the New York Academy of Sciences.

[10]  H. Kittler,et al.  BRAF kinase gene V599E mutation in growing melanocytic lesions. , 2004, Journal of Investigative Dermatology.

[11]  H. Moses,et al.  Tumor-stroma interactions. , 2005, Current opinion in genetics & development.

[12]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[13]  S. Bézieau,et al.  A ras-Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma Lesion1 , 2002, The Journal of Immunology.

[14]  Christopher J. Miller,et al.  Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. , 2004, The Journal of investigative dermatology.

[15]  M. Pierotti,et al.  BRAF alterations are associated with complex mutational profiles in malignant melanoma , 2004, Oncogene.

[16]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[17]  R. Weinberg,et al.  Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. , 2003, Cancer cell.

[18]  J. Durocher,et al.  High Sensitivity Scanning of Colorectal Tumors and Matched Plasma DNA for Mutations in APC, TP53, K‐RAS, and BRAF Genes with a Novel DHPLC Fluorescence Detection Platform , 2004, Annals of the New York Academy of Sciences.

[19]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[20]  Åsa Sivertsson,et al.  Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases. , 2002, Clinical chemistry.

[21]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[22]  D. Schadendorf,et al.  Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. , 2005, Carcinogenesis.

[23]  R. Marais,et al.  The role of B-RAF in melanoma , 2005, Cancer and Metastasis Reviews.

[24]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[25]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Markus Ringnér,et al.  Microarray expression profiling in melanoma reveals a BRAF mutation signature , 2004, Oncogene.

[27]  J. Hoeffler,et al.  Ras mutations in human melanoma: a marker of malignant progression. , 1994, The Journal of investigative dermatology.

[28]  U. Ringborg,et al.  N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. , 1998, The Journal of investigative dermatology.

[29]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[30]  F. Lozupone,et al.  Effect Of Human Natural Killer and γδ T Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice , 2004, Cancer Research.

[31]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.